调强放疗联合化疗治疗直肠癌术后复发的临床观察  

Clincial Study of Postoperative Local Recurrence Rectal Cancer Treated by Combining Intensity-modulated Radiotherapy and Chemotherapy

作　　者：程文芳[1] 张和平[1] 吴君心[1] 

机构地区：[1]福建医科大学教学医院福建省肿瘤医院,350014

出　　处：《实用癌症杂志》2011年第4期383-386,共4页The Practical Journal of Cancer

摘　　要：目的探讨调强放疗联合化疗治疗直肠癌术后复发的价值。方法 2005年12月～2007年12月我院直肠癌根治性切除术后复发患者42例,均接受调强放射治疗(2 Gy/次,5次/周,总剂量66～68 Gy,6～7周完成),同时进行化疗(5-FU、CF和奥铂)。经随访观察,予回顾性分析。结果治疗总有效率(CR+PR)为85.7%(36/42),症状缓解率为95.2%(40/42)。中位生存期35.5个月。1、2、3年生存率分别为87.5%、85.8%、26.3%;1、2、3年无进展生存率分别为83.8%、83.8%、16.9%,急性放射反应主要是急性放射性肠炎和骨髓抑制,多为1～2级。结论调强放射治疗结合化疗可提高术后局部复发直肠癌的总生存率和无进展生存率,并能减少放射治疗反应。Objective To evaluate the value of postoperative local recurrence rectal cancer treated by combining Intensity-modulated radiotherapy and chemotherapy.Methods From Dec.2005 to Dec.2007,forty-two patients with postoperative local recurrence rectal cancer were treated by combining IMRT（2Gy/Fx,5 times/Week,DT 66-68Gy,6-7week） and chemotherapy（5-Fu,CF and Oxaliplatin）.After following up and observing,we made a retrospective analysis.Results The total treatment efficacy（（CR＋PR） was 85.7%（36/42）;Symptom relief rate was 95.2%（40/42）.The median survival time was 35.5 months.1,2 and 3 years progression-free survival rates were 87.5%、78.8%、26.3%.1,2 and 3 years overall survival rates were 83.8%、83.8%、16.9%,respectively.Acute radiation side effects included radiation restitis and leukopenia were observed,and its degree varied mainly from grade 1 to grade 2.Conclusion Intensity modulated radiation therapy combined with chemotherapy for postoperative local recurrence rectal cancer can improve local control、survival rates and reduce acute radiation side effects.

关 键 词：直肠肿瘤 复发 调强放射治疗 化疗疗法 

分 类 号：R735.37[医药卫生—肿瘤]